Literature DB >> 11736946

Pruritus in polycythaemia vera: prevalence, laboratory correlates and management.

F Diehn1, A Tefferi.   

Abstract

In a retrospective cohort, 192 (48%) out of 397 patients with polycythaemia vera had a documented history of pruritus. At diagnosis, the presence of pruritus was significantly associated with a lower mean corpuscular volume and a higher leucocyte count. Among 66 patients with documentation of treatment for pruritus, 389 'patient visits' were reviewed, revealing a significant correlation between active pruritus and low mean corpuscular volume, but not platelet, leucocyte or basophil count. Paroxetine and hydroxyzine were rated by patients to be the most effective drugs in controlling pruritus. These observations suggest a pathogenetic role for both iron deficiency and biogenic amines in polycythaemia vera-associated pruritus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736946     DOI: 10.1046/j.1365-2141.2001.03161.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.

Authors:  Kathleen Jentsch-Ullrich; Judith Eberhardt; Vanja Zeremski; Michael Koehler; Denise Wolleschak; Florian H Heidel
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-18       Impact factor: 4.553

Review 2.  Molecular and cellular mechanisms that initiate pain and itch.

Authors:  Jialie Luo; Jing Feng; Shenbin Liu; Edgar T Walters; Hongzhen Hu
Journal:  Cell Mol Life Sci       Date:  2015-04-18       Impact factor: 9.261

Review 3.  Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates.

Authors:  Andrea L Suárez; Jamison D Feramisco; John Koo; Martin Steinhoff
Journal:  Acta Derm Venereol       Date:  2012-01       Impact factor: 4.437

Review 4.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  Novel and emerging therapies for the treatment of polycythemia vera.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Expert Rev Hematol       Date:  2014-10-29       Impact factor: 2.929

Review 6.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

Review 7.  [Pruritus with systemic diseases].

Authors:  T Mettang; M Streit; E Weisshaar
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

8.  The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.

Authors:  Lisa Pieri; Costanza Bogani; Paola Guglielmelli; Maria Zingariello; Rosa Alba Rana; Niccolò Bartalucci; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

9.  Pruritus in certain internal diseases.

Authors:  D Yonova
Journal:  Hippokratia       Date:  2007-04       Impact factor: 0.471

Review 10.  Itch and Cough - Similar Role of Sensory Nerves in Their Pathogenesis.

Authors:  T Pecova; I Kocan; R Vysehradsky; R Pecova
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.